Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

It is with great sadness that we learnt of the death of Sir David Weatherall this weekend.

None

Sir David Weatherall, fondly called ‘Prof’ by those who knew him, was a general physician, a haematologist and clinician scientist whose research focused on the genetics of blood disorders affecting haemoglobin, such as thalassaemia and sickle cell disease. Together with his long-standing scientific colleague John Clegg, David developed new methods for measuring the synthesis of the alpha and beta chains of Haemoglobin, providing the first clear evidence of how thalassaemia arises. David’s work made it possible to detect these common genetic disorders early in pregnancy, enabling antenatal diagnosis.

His characterisation of the mutations causing thalassaemia enabled numerous families to be offered genetic counselling and led to the eradication of thalassaemia in some parts of the world. His work sparked the revolution in the application of molecular biology to all aspects of clinical medicine starting over 30 years ago when he established the first Institute of Molecular Medicine in the UK, based at the John Radcliffe Hospital in Oxford, and part of the University of Oxford.

Read more (University of Oxford website)

Similar stories

Peter Horby receives prestigious award for outstanding service to public health

The Faculty of Public Health (FPH) has awarded its prestigious Alwyn Smith Prize to Professor Sir Peter Horby (Nuffield Department of Medicine) for 2020/2021 in recognition of his outstanding service to public health as a global leader in epidemic science.

Six new Fellowships announced as part of Oxford-Bristol Myers Squibb Fellowships Programme

The Oxford - Bristol Myers Squibb (BMS) Fellowships Programme continued to demonstrate significant progress over the last year, despite the challenges associated with the global pandemic, including restricted lab access and work from home guidance. Today, we are pleased to announce six new Oxford-BMS Fellowships for 2021.

Researchers set out steps to address mental health effects of the pandemic on young people

Researchers have outlined 14 steps that schools, mental health services and policymakers can take to help children and young people whose mental health has been affected by the COVID-19 pandemic.

Anti-cancer drug derived from fungus shows promise in clinical trials

A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana as found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.

Professor Trish Greenhalgh Highly Commended in the O²RB Excellence in Impact Awards 2021

Congratulations to Professor Trish Greenhalgh (Nuffield Department of Primary Care Health Sciences) who has been Highly Commended in the O²RB Excellence in Impact Awards 2021.

No benefit of convalescent plasma for critically ill COVID-19 patients

A large study of over 2000 COVID-19 patients has found that giving critically ill patients blood plasma from recovered COVID-19 patients did not significantly reduce deaths, or the need for intensive care support such as being put on a ventilator machine.